Big Pharma Split Corp.
PRM.TOTSXFinancial Services● Active
$13.75
+$0.12(+0.88%)
Market Cap$17933259
P/E Ratio—
52W High$15.5
52W Low$10.71
Big Pharma Split Corp. (PRM.TO) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · PRM.TO · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $1.45M | $1.85M | $0.31M | $3.93M | $5.36M |
| Cost of Revenue | $0.31M | $0.32M | $0.31M | $0.42M | $0.36M |
| Gross Profit | $1.14M | $1.53M | $0.31M | $3.51M | $5.00M |
| Gross Margin %(computed) | 78.42% | 82.91% | 100.00% | 89.31% | 93.36% |
| Operating Expenses | |||||
| R&D Expenses | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| G&A Expenses | $0.00M | $0.54M | $0.33M | $0.36M | $0.37M |
| Total Operating Expenses | ($3.89M) | $0.54M | $0.45M | $0.57M | ($4.46M) |
| Operating Income | $5.03M | $0.01M | ($0.14M) | $3.15M | $4.85M |
| Operating Margin %(computed) | 346.00% | 0.73% | -44.80% | 80.12% | 90.56% |
| Interest Income | $0.00M | $0.00M | $0.00M | $0.76M | $0.69M |
| Interest Expense | $0.64M | $0.56M | $0.51M | $0.76M | $0.88M |
| Income Before Tax | $4.40M | ($0.54M) | ($0.65M) | $2.39M | $4.85M |
| Income Tax Expense | $0.00M | $0.00M | ($0.51M) | $0.00M | $0.00M |
| Net Income | $4.40M | ($0.54M) | ($0.14M) | $3.15M | $4.85M |
| Net Margin %(computed) | 302.72% | -29.13% | -44.80% | 80.12% | 90.56% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $3.59 | $-0.47 | $-0.53 | $1.58 | $3.27 |
| Wtd Avg Shares | 1.22M | 1.15M | 1.22M | 1.51M | 1.29M |
| EBITDA | $5.03M | $0.02M | ($0.14M) | $3.15M | $4.85M |
| EBITDA Margin %(computed) | 346.00% | 1.16% | -44.12% | 80.12% | 90.56% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · CAD · M
Explore more Big Pharma Split Corp. data
About Big Pharma Split Corp. (PRM.TO) Income Statement
Big Pharma Split Corp. (PRM.TO) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, PRM.TO reported revenue of $0.00B, gross profit of $0.00B (gross margin 78.42%), and net income of $0.00B — a net profit margin of 302.72%.
Frequently asked questions
PRM.TO · 4 questionsBig Pharma Split Corp. (PRM.TO) reported revenue of $0.00B for 2025, down 21.4% year-over-year.
PRM.TO revenuePRM.TO salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09